competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.
Scope of the Gene therapy analysis report:
Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success –
– Why do gene therapies still occupy only a minimal market share in their respective indications? – What can be learned from the gene therapies that have already reached the market? A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies – – What are the relative advantages and disadvantages of each vector type and which hold the most promise? – What proportion of the overall gene therapy R & D pipeline is occupied by each vector type?
The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50 % are gene silencing therapies, while 31 % involve the insertion of a functional gene – – In which therapy areas is there the highest level of R & D activity for gene therapies? – At which stage of development does the majority of pipeline gene therapies reside? – What is the proportion of the pipeline occupied by each intervention and vector type overall? A number of companies are currently actively developing pipeline gene therapies, including private, public and institutional enterprises – – How do gene therapies fit into the overall portfolios of these companies? – What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?
Get 15 % Discount on Single User License of Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook Market Research Report at – www. absolutereports. com / enquiry / request-discount / 10075327
Offer valid till 1 st July 2016
The report will allow to –
– Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and